Results 101 to 110 of about 374,365 (198)

Health care provider and client experiences of counselling on depot medroxyprogesterone acetate subcutaneous (DMPA-SC) for self-injection in Malawi. [PDF]

PLOS Glob Public Health, 2023
Porter Erlank C, Ali G, Birhanu F, Stanley M, Chirwa JS, Kachale F, Gunda A.   +6 more
europepmc   +1 more source

Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma. [PDF]

Obstet Gynecol, 2022
Harmon QE, Patchel SA, Zhao S, Umbach DM, Cooper TE, Baird DD.   +5 more
europepmc   +1 more source

Patient's experience and satisfaction with self-administered subcutaneous depot medroxyprogesterone acetate use during the first year of COVID-19. [PDF]

Contraception, 2023
Smith TJ, Urdanigo TK, Shroff N, Rubin SE.   +3 more
europepmc   +1 more source

Depot medroxyprogesterone acetate versus norethisterone oenanthate for long-acting progestogenic contraception : a systematic review

, 2006
Includes bibliographical references.[Background] Two injectable progestogen-only contraceptives (IPCs) depot medroxyprogesterone acetate (DMPA) and norethisterone oenanthate (NET-EN) continue to be extensively used in some countries, forming a large ...
Draper, Beverly
core   +1 more source

sj-docx-1-app-10.1177_27551857241246753 - Supplemental material for Spectral Analysis of Injectable Depot Medroxyprogesterone Acetate From the International Market With Diffuse Reflectance Spectrometers: Potential Public Health Implications With Benchtop and Handheld Spectrometers

Supplemental material, sj-docx-1-app-10.1177_27551857241246753 for Spectral Analysis of Injectable Depot Medroxyprogesterone Acetate From the International Market With Diffuse Reflectance Spectrometers: Potential Public Health Implications With Benchtop ...
Matthew Eady (18451177), Jeffery Tremelling (18451180), Steven Hamel (15140832), David Jenkins (295958)   +3 more
core   +1 more source

Depot medroxyprogesterone acetate (Depo-Provera) as a contraceptive preparation.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1971
Experience with depot medroxyprogesterone acetate as a contraceptive preparation in 7 335 patients for a total of 38 714 months over a 3-year period is described. The discontinuation rate was 18.3% and the failure rate 0-35 per 100 women-years of use. This compares very well with all other methods of contraception.
openaire   +2 more sources

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate. [PDF]

Contracept X, 2022
Taylor DJ, Halpern V, Brache V, Bahamondes L, Jensen JT, Dorflinger LJ.   +5 more
europepmc   +1 more source

Genomic hallmarks of depot medroxyprogesterone acetate-associated meningiomas. [PDF]

Neuro Oncol
Huq S, Gatesman TA, Abou-Al-Shaar H, Raleigh DR, Hadjipanayis CG, Bayley JC, Zenonos GA, Pearce TM, Marker DF, Agnihotri S, Gardner PA.   +10 more
europepmc   +1 more source

Green Tea Extract has a Protective Effect on Leptin and Lipid Profile Levels Due to the Induction of Depot Medroxyprogesterone Acetate. [PDF]

Med Arch, 2023
Wahyuni ES, Maryatun M, Veri N, Susilawati E, Firrahmawati L, Wahyuni ES, Wulandari R.   +6 more
europepmc   +1 more source

The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant. [PDF]

J Infect Dis, 2022
Tanko RF, Bunjun R, Dabee S, Jaumdally SZ, Onono M, Nair G, Palanee-Phillips T, Harryparsad R, Happel AU, Gamieldien H, Qumbelo Y, Sinkala M, Scoville CW, Heller K, Baeten JM, Bosinger SE, Burgener A, Heffron R, Jaspan HB, Passmore JAS.   +19 more
europepmc   +1 more source